Health Commissioner Kyriakides on EU Vaccine Strategy

The transcript discusses the progress of Pfizer's COVID-19 vaccine, highlighting its 90% efficiency and the EU's contract for 300 million doses. It outlines the EU's vaccine strategy, emphasizing solidarity and distribution based on population. The EU aims for a diversified vaccine portfolio, involving multiple pharmaceutical companies. The approval process by the European Medicines Agency is crucial for safety and effectiveness. The timeline suggests potential vaccine availability by early 2021, with significant societal and economic implications. The EU is learning from the pandemic to enhance future public health responses.

How does the EU plan to ensure equitable distribution of the vaccine among Member States?

What is the expected timeline for the vaccine to be available to the public?

What lessons were learned from the first lockdown that could improve the response to the current situation?